Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation.
Adolescent
Adult
Aged
Allografts
Antigens, CD34
/ metabolism
Bone Marrow Cells
/ metabolism
Disease-Free Survival
Female
Graft vs Host Disease
/ metabolism
Hematopoietic Stem Cell Transplantation
Humans
Male
Methotrexate
/ administration & dosage
Middle Aged
Mycophenolic Acid
/ administration & dosage
Retrospective Studies
Survival Rate
T-Lymphocyte Subsets
/ metabolism
Transplantation Conditioning
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
06
04
2018
accepted:
13
10
2018
revised:
02
10
2018
pubmed:
31
10
2018
medline:
2
7
2020
entrez:
31
10
2018
Statut:
ppublish
Résumé
Donor-derived T-cells mediate graft-versus-leukemia effect, immune reconstitution, and graft-versus-host-disease (GvHD) after allogeneic hematopoietic cell transplantation (HCT). We examined the association of donor cell subsets with outcomes in recipients of myeloablative allogeneic HCT using bone marrow (BM, N = 359) grafts from 2002 to 2014 with related or unrelated donors. Analysis considered pre-infusion graft total nucleated cell (TNC), CD34+ CD3+, CD4+, CD8+ doses. Most patients received busulfan-cyclophosphamide or etoposide-total body irradiation conditioning for acute leukemia or myelodysplastic syndrome. Calcineurin inhibitor-mycophenolate mofetil (CNI-MMF) (49%) or calcineurin inhibitor-methotrexate (CNI-MTX) (47%) were used for GvHD prophylaxis. In multivariable analysis, higher CD34+ dose was associated with platelet engraftment (P < 0.001) and lymphocyte recovery (P = 0.006). There was no association of donor cell subsets with donor chimerism or overall survival. In conclusion, BM graft composition is associated with myeloablative allogeneic HCT outcomes and future studies to evaluate optimal graft composition are needed.
Identifiants
pubmed: 30375493
doi: 10.1038/s41409-018-0380-5
pii: 10.1038/s41409-018-0380-5
doi:
Substances chimiques
Antigens, CD34
0
Mycophenolic Acid
HU9DX48N0T
Methotrexate
YL5FZ2Y5U1
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
775-781Références
Yakoub-Agha I, Saule P, Depil S, Grutzmacher C, Boulanger F, Magro L, et al. Comparative analysis of naive and memory CD4+and CD8+T-cell subsets in bone marrow and G-CSF-mobilized peripheral blood stem cell allografts: impact of donor characteristics. Exp Hematol. 2007;35(6):861–71.
doi: 10.1016/j.exphem.2007.03.006
Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, et al. High graft CD8 cell dose predicts improved survival and enables better donor selection in allogeneic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2015;33(21):2392–8.
doi: 10.1200/JCO.2014.60.1203
Remberger M, Torlen J, Ringden O, Engstrom M, Watz E, Uhlin M, et al. Effect of total nucleated and CD34(+) cell dose on outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(5):889–93.
doi: 10.1016/j.bbmt.2015.01.025
Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;34(7):621–5.
doi: 10.1038/sj.bmt.1704647
Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, et al. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. Am J Hematol. 2015;90(2):144–8.
doi: 10.1002/ajh.23882
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.
doi: 10.1182/blood-2005-05-2004
Transplantation ASoBaM. ASBMT RFI - Disease Classifications Corresponding to CIBMTR Classification. 2017.
O’Keefe CL, Sobecks RM, Wlodarski M, Rodriguez A, Bell K, Kuczkowski E, et al. Molecular TCR diagnostics can be used to identify shared clonotypes after allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2004;32(10):1010–22.
doi: 10.1016/j.exphem.2004.07.013
O’Keefe CL, Gondek L, Davis R, Kuczkowski E, Sobecks RM, Rodriguez A, et al. Molecular analysis of alloreactive CTL post-hemopoietic stem cell transplantation. J Immunol. 2007;179(3):2013–22.
doi: 10.4049/jimmunol.179.3.2013
Bayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, et al. Optimal threshold and time of absolute lymphocyte count assessment for outcome prediction after bone marrow transplantation. Biol Blood Marrow Transplant. 2016;22(3):505–13.
doi: 10.1016/j.bbmt.2015.10.020
Bittencourt H, Rocha V, Chevret S, Socie G, Esperou H, Devergie A, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;99(8):2726–33.
doi: 10.1182/blood.V99.8.2726
Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger-Villard F, et al. A high proportion of donor CD4+T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy. Leukemia. 2006;20(9):1557–65.
doi: 10.1038/sj.leu.2404308
Chang YJ, Zhao XY, Huo MR, Huang XJ. Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation. J Clin Immunol. 2009;29(5):696–704.
doi: 10.1007/s10875-009-9293-9
Choufi B, Thiant S, Trauet J, Cliquennois M, Cherrel M, Boulanger F, et al. [The impact of donor naive and memory T cell subsets on patient outcome following allogeneic stem cell transplantation: relationship between infused donor CD4+/CCR7+T cell subsets and acute graft-versus-host disease]. Pathol Biol (Paris). 2014;62(3):123–8.
doi: 10.1016/j.patbio.2014.02.013
Gooptu M, Kim HT, Chen YB, Rybka W, Artz A, Boyer M et al. Effect of antihuman T lymphocyte globulin on immune recovery after myeloablative allogeneic stem cell transplantation with matched unrelated donors: analysis of immune reconstitution in a double-blind randomized controlled trial. Biol Blood Marrow Transplant. 2018;pii: S1083-891:3038–2.
Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Ball E, Cook D, et al. CD8+T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone Marrow Transplant. 2005;35(3):247–52.
doi: 10.1038/sj.bmt.1704736
Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi S, et al. Improved survival after transplantation of more donor plasmacytoid dendritic or naive T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. J Clin Oncol. 2014;32(22):2365–72.
doi: 10.1200/JCO.2013.54.4577
Perreault C, Decary F, Brochu S, Gyger M, Belanger R, Roy D. Minor histocompatibility antigens. Blood. 1990;76(7):1269–80.
pubmed: 2207305
Perreault C, Allard A, Brochu S, Poupart C, Fontaine P, Belanger R, et al. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice. Bone Marrow Transplant. 1990;6(2):127–35.
pubmed: 2145050
Pidala J, Sarwal M, Roedder S, Lee SJ. Biologic markers of chronic GVHD. Bone Marrow Transplant. 2014;49(3):324–31.
doi: 10.1038/bmt.2013.97
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.
doi: 10.1016/j.bbmt.2009.06.019
Theilgaard-Monch K, Raaschou-Jensen K, Schjodt K, Heilmann C, Vindelov L, Jacobsen N, et al. Pluripotent and myeloid-committed CD34+subsets in hematopoietic stem cell allografts. Bone Marrow Transplant. 2003;32(12):1125–33.
doi: 10.1038/sj.bmt.1704297
Rocha V, Carmagnat MV, Chevret S, Flinois O, Bittencourt H, Esperou H, et al. Influence of bone marrow graft lymphocyte subsets on outcome after HLA-identical sibling transplants. Exp Hematol. 2001;29(11):1347–52.
doi: 10.1016/S0301-472X(01)00737-8
Kalwak K, Porwolik J, Mielcarek M, Gorczynska E, Owoc-Lempach J, Ussowicz M, et al. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant. 2010;16(10):1388–401.
doi: 10.1016/j.bbmt.2010.04.001
Loschi M, Porcher R, Peffault de Latour R, Vanneaux V, Robin M, Xhaard A, et al. High number of memory t cells is associated with higher risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(3):569–74.
doi: 10.1016/j.bbmt.2014.12.009